Segment Data (Tables)

3 Months Ended

Mar. 26, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:

	Three Months Ended
	March 26, 2021		March 27, 2020
Net sales:
Specialty Brands	$	408.4	$	490.6
Specialty Generics	149.6		175.2
Net sales	$	558.0	$	665.8
Operating loss:
Specialty Brands	$	212.1	$	220.5
Specialty Generics	31.7		63.2
Segment operating income	243.8		283.7
Unallocated amounts:
Corporate and unallocated expenses (1)	(22.6)		(57.5)
Depreciation and amortization	(169.6)		(223.1)
Share-based compensation	(3.6)		(6.7)
Restructuring charges, net	(0.4)		1.8
Non-restructuring impairment charges	(64.5)		—
Separation costs (2)	(0.6)		(21.3)
Opioid-related litigation settlement gain (3)	—		16.8
Operating loss	$	(17.5)	$	(6.3)

(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(2)Represents costs included in SG&A expenses, primarily related to professional fees and costs incurred in preparation for the Chapter 11 proceedings. As of the Petition Date, professional fees directly related to the Chapter 11 proceedings that were previously reflected as separation costs are being classified on a go-forward basis as reorganization items, net.

(3)Represents the change in the Settlement Warrants' fair value. Refer to Note 11 for further information.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:

	Three Months Ended
	March 26, 2021		March 27, 2020
Acthar Gel (1)	$	129.0	$	167.6
INOmax	134.0		141.7
Ofirmev	12.8		74.9
Therakos	66.8		63.7
Amitiza (2)	61.4		41.1
Other	4.4		1.6
Specialty Brands	408.4		490.6
Hydrocodone (API) and hydrocodone-containing tablets	23.3		26.5
Oxycodone (API) and oxycodone-containing tablets	17.2		16.9
Acetaminophen (API)	45.5		44.1
Other controlled substances	58.1		83.6
Other	5.5		4.1
Specialty Generics	149.6		175.2
Net sales	$	558.0	$	665.8

(1)The three months ended March 26, 2021 includes the prospective change to the Medicaid rebate calculation that began in June 2020, which impacted Acthar Gel net sales by $12.5 million. See Note 11 for further detail on the status of the Medicaid lawsuit.

(2)Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.